%%%%%%%%%%%% Program Specific Acronyms: %%%%%%%%%%%%%%%
% Program specific acronyms, such as disease, population, drugs, etc. are to be defined here
% Keep them separate from the general acronyms enables cleansing of project-specific info, if needed



%%%%%%%%%%%% General Acronyms: %%%%%%%%%%%%%%%
%General acronyms are to be defined here
%%%%%%%%% A
\newacronym{ADAM}{ADaM}{analysis data model}
\newacronym{AE}{AE}{adverse event}
\newacronym{AIC}{AIC}{Akaike information criterion}
\newacronym{ALAG}{ALAG}{oral absorption lag time}
\newacronym{ALT}{ALT}{alanine aminotransferase}
\newacronym{ASCII}{ASCII}{American Standard Code for Information Interchange}
\newacronym{AST}{AST}{aspartate aminotransferase}
\newacronym[sort=AUC]{AUC}{\ensuremath{\mathrm{AUC}}}{area under the concentration-time curve}
\newacronym[sort=AUCtau]{AUCtau}{\ensuremath{\mathrm{AUC}_{\tau}}}{area under the concentration-time curve during the dosing interval}
\newacronym[sort=AUCss]{AUCss}{\ensuremath{\mathrm{AUC_{\mathrm{ss}}}}}{area under the concentration-time curve for a dosing interval at steady-state}
\newacronym[sort=AUCC]{AUCC}{\ensuremath{AUC_{\mathrm{cumulative}}}}{cumulative area under the concentration-time curve since first dose}
\newacronym{AWS}{AWS}{Amazon web services}

%%%%%%%%% B
\newacronym{BALT}{BALT}{baseline alanine aminotransferase}
\newacronym{BAST}{BAST}{baseline aspartate aminotransferase}
\newacronym{BID}{BID}{twice daily}
\newacronym{BBIL}{BBIL}{baseline bilirubin}
\newacronym{BIL}{BILI}{bilirubin}
\newacronym{BLQ}{BLQ}{below the limit of quantitation}
\newacronym{BMI}{BMI}{body mass index}
\newacronym{BOV}{BOV}{between occasion variability}
\newacronym{BSA}{BSA}{body surface area}
\newacronym{BBW}{BBW}{baseline body weight}

%%%%%%%%% C
\newacronym{CATD}{CATD}{computer assisted clinical trial design}
\newacronym[sort=Cavg]{Cavg}{\ensuremath{C_{\mathrm{avg}}}}{average concentration during the dosing interval}
\newacronym[sort=Cavgc]{Cavgc}{\ensuremath{C_{\mathrm{avg,\sim cumulative}}}}{average concentration since first dose calculated as $AUC_{\mathrm{cumulative}}$/TAFD}
\newacronym[sort=Cavgss]{Cavgss}{\ensuremath{C_{\mathrm{avg,ss}}}}{average concentration during the dosing interval at steady-state}
\newacronym{CKDAP}{CKD-aP}{chronic kidney disease associated pruritus}
\newacronym{CKD}{CKD}{chronic kidney disease}
\newacronym[plural=CIs, firstplural=confidence intervals (CIs)]{CI}{CI}{confidence interval}
\newacronym{CL}{CL}{drug clearance}
\newacronym{CLr}{CLr}{renal clearance}
\newacronym[sort=CLi]{CLi}{\ensuremath{\mathrm{CL_i}}}{individual-specific systemic clearance}
\newacronym[sort=CLF]{CLF}{\ensuremath{\mathrm{CL/F}}}{apparent clearance after oral dosing}
\newacronym[sort=Cmax]{Cmax}{\ensuremath{\mathrm{C}_{\mathrm{max}}}}{maximum concentration in the dosing interval}
\newacronym[sort=Cmaxss]{Cmaxss}{\ensuremath{C_{\mathrm{max,ss}}}}{maximum concentration in the dosing interval at steady-state}
\newacronym[sort=Cmin]{Cmin}{\ensuremath{C_{\mathrm{min}}}}{minimum concentration in the dosing interval}
\newacronym[sort=Ctrough]{Ctrough}{\ensuremath{C_{\mathrm{trough}}}}{minimum concentration in the dosing interval}
\newacronym[sort=Cminss]{Cminss}{\ensuremath{C_{\mathrm{min,ss}}}}{minimum concentration in the dosing interval at steady-state}
\newacronym{CNS}{CNS}{central nervous system}
\newacronym[sort=CLcr]{CLcr}{\ensuremath{\mathrm{CL_{cr}}}}{creatinine clearance}
\newacronym{CSR}{CSR}{clinical study report}
\newacronym{CSV}{CSV}{comma separated values}
\newacronym{CVP}{\%CV}{percent coefficient of variation}
\newacronym{CWRES}{CWRES}{conditional weighted residual}

%%%%%%%%% D
\newacronym{D1}{D1}{zero-order release into an absorption compartment}
\newacronym{df}{df}{degrees of freedom}
\newacronym{DV}{DV}{dependent variable}

%%%%%%%%% E
\newacronym[plural=EBEs, firstplural=empirical Bayes estimate (EBEs)]{EBE}{EBE}{empirical Bayes estimate}
\newacronym{ECG}{ECG}{electrocardiogram}
\newacronym{EDTA}{EDTA}{edetic acid}
\newacronym{eGFR}{eGFR}{estimated glomerular filtration rate}
\newacronym{EM}{EM}{expectation maximization}
\newacronym{ETA}{\ensuremath{\eta}}{interindividual variability}
\newacronym{EPS}{\ensuremath{\epsilon}}{residual variability}

%%%%%%%%%
\newacronym[sort=f]{F}{\ensuremath{F}}{absolute bioavailability}
\newacronym[sort=fe]{fe}{\ensuremath{f_e}}{percent of IV dose excreted unchanged in the urine reported by collection interval and total \% dose excreted}
\newacronym{FDA}{FDA}{Food and Drug Administration}
\newacronym{FO}{FO}{first-order}
\newacronym{FOCEI}{FOCEI}{first-order conditional estimation with $\eta$--$\epsilon$\ interaction}
\newacronym{FPG}{FPG}{fasting plasma glucose}
%\newacronym{F1}{\ensuremath{\mathrm{F1_{logTrans}}}}{logistic transformation for F1}
\newacronym{F1}{F1}{bioavailability}


%%%%%%%%% G
\newacronym{Rhat}{R-hat}{Gelman-Rubin diagnostics}
\newacronym{GFR}{GFR}{glomerular filtration rate}
\newacronym{gh}{HbA1c}{glycosylated hemoglobin}
\newacronym{GOF}{GOF}{goodness of fit}
%%%%%%%%% H
\newacronym{hr}{hr}{hours}

%%%%%%%%% I
\newacronym{IBW}{IBW}{ideal body weight}
\newacronym{IGF-1}{IGF-1}{insulin-like growth factor 1}
\newacronym{IIV}{IIV}{interindividual variability}
\newacronym{IMP}{IMP}{importance sampling Monte Carlo}
\newacronym{ITS}{ITS}{iterative two stage}
\newacronym{IV}{IV}{intravenous}
\newacronym{IPRED}{IPRED}{individual model predictions}
%%%%%%%%% J

%%%%%%%%% K
\newacronym[sort=ka]{ka}{\ensuremath{k_a}}{first order absorption rate constant}
\newacronym{kg}{kg}{kilograms}
\newacronym{KDOQI}{K/DOQI}{Kidney Disease Outcome Quality Initiative}


%%%%%%%%% L
\newacronym{L}{L}{liters}
\newacronym{LL}{LL}{log likelihood}
\newacronym{LLC}{LLC}{3,0-Lauroyl-L-carnitine}
\newacronym{LLOQ}{LLOQ}{lower limit of quantitation}
\newacronym{LRT}{LRT}{likelihood ratio test}

%%%%%%%%% M
\newacronym{MAP}{MAP}{maximum a posteriori}
\newacronym{mcg}{mcg}{micrograms}
\newacronym{MCMC}{MCMC}{Markov chain Monte Carlo}
\newacronym{mg}{mg}{milligrams}
\newacronym{mL}{mL}{milliliters}
\newacronym{MDRD}{MDRD}{modification of diet in renal disease}
\newacronym{MS}{M\&S}{modeling and simulation}
\newacronym{MSP}{MSP}{modeling and simulation plan}
\newacronym{MU}{$\mu$}{population PK parameter in the logarithmic domain}
\newacronym{MUs}{$\mu$}{population PK parameters in the logarithmic domain}
%%%%%%%%%
\newacronym{NCA}{NCA}{noncopartmental analysis}
\newacronym{NCI}{NCI}{National Cancer Institute}
\newacronym{Neff}{Neff}{effective sample size}
\newacronym{NPDE}{NPDE}{normalized prediction distribution error}
\newacronym{NLME}{NLME}{nonlinear mixed-effect}
\newacronym{ng}{ng}{nanograms}
\newacronym{NONMEM}{NONMEM}{nonlinear mixed-effects modeling}
\newacronym[sort=N]{etai}{\ensuremath{\eta i}}{individual random effects}


%%%%%%%%% O
\newacronym{ODWG}{ODWG}{organ dysfunction working group}
\newacronym{OFV}{OFV}{objective function value}
\newacronym{OMEGA}{\ensuremath{\omega^2}}{interindividual variability variance}
%%%%%%%%% P
\newacronym{PD}{PD}{pharmacodynamic(s)}
\newacronym{PK}{PK}{pharmacokinetic(s)}
\newacronym{pg}{pg}{picograms}
\newacronym{PNS}{PNS}{peripheral nervous system}
\newacronym{PO}{PO}{orally}
\newacronym[plural=PPCs, firstplural=posterior predictive checks (PPCs)]{PPC}{PPC}{posterior predictive check}
\newacronym{PRED}{PRED}{population model predictions}

%%%%%%%%% Q
\newacronym{Q}{Q}{intercompartmental clearance}
% \newacronym{Q2}{\ensuremath{Q_2}}{intercompartmental clearance}
% \newacronym{Q3}{\ensuremath{Q_3}}{intercompartmental clearance}
\newacronym[sort=Q2]{Q2}{\ensuremath{\mathrm{Q_2}}}{intercompartmental clearance (central and first peripheral compartments)}
\newacronym[sort=Q3]{Q3}{\ensuremath{\mathrm{Q_3}}}{intercompartmental clearance (central and second peripheral compartments)}
\newacronym{QD}{QD}{once daily}
\newacronym[sort=QF]{QF}{\ensuremath{\mathrm{Q/F}}}{apparent (oral) intercompartmental clearance}

%%%%%%%%% R
\newacronym{RES}{RES}{residuals}
\newacronym{RI}{RI}{renal impairment}
\newacronym{ROPE}{ROPE}{region of practical equivalence}
\newacronym{RDV}{RDV}{remdesivir, Veklury{\textregistered}}
\newacronym{RSE}{RSE}{relative standard error}
\newacronym{RRT}{RRT}{renal replacement therapy}
%%%%%%%%% S
\newacronym{SAEM}{SAEM}{stochastic approximation expectation maximization}
\newacronym{SCR}{SCR}{serum creatinine}
\newacronym{SD}{SD}{single dose}
\newacronym{SDV}{SDV}{standard deviation}
\newacronym{SDTM}{SDTM}{submission data tabulation model}
\newacronym{SE}{SE}{standard errors}
\newacronym{SIR}{SIR}{sampling importance resampling}
\newacronym{ss}{ss}{steady-state}
\newacronym{SGLT}{SGLT}{sodium-dependent glucose cotransporters}
\newacronym{SBECD}{SBECD}{sulfobutylether-\ensuremath{\beta}-cyclodextrin}
\newacronym{SIGMA}{\ensuremath{\sigma^2}}{residual variability variance}
%%%%%%%%% T
\newacronym{TAD}{TAD}{time after most recent dose}
\newacronym{Tmax}{Tmax}{time to reach maximum concentration}
\newacronym{TAFD}{TAFD}{time after first dose}
\newacronym[sort=TVP]{TVP}{\ensuremath{\mathrm{TVP}}}{typical value of a model parameter  $P$}
\newacronym{T2DM}{T2DM}{type 2 diabetes mellitus}
\newacronym[sort=t]{hl}{\ensuremath{t_{1/2}}}{elimination half-life}
\newacronym{THETA}{\ensuremath{\theta}}{population fixed-effects}

%%%%%%%%% U
\newacronym{UKPDS}{UKPDS}{United Kingdom Prospective Diabetes Study}

%%%%%%%%% V
\newacronym[sort=Vd]{Vd}{\ensuremath{\mathrm{V_d}}}{volume of distribution}
\newacronym[sort=VF]{VF}{\ensuremath{V/F}}{apparent volume of distribution after oral dosing}
\newacronym[sort=V1F]{V1F}{\ensuremath{\mathrm{V_1/F}}}{apparent central volume of distribution after oral dosing}
\newacronym[sort=V2F]{V2F}{\ensuremath{\mathrm{V_2/F}}}{apparent peripheral volume of distribution after oral dosing}
% \newacronym[sort=V1]{V1}{\ensuremath{V_1}}{central volume of distribution}
% \newacronym[sort=V2]{V2}{\ensuremath{\mathrm{V_2}}}{volume of distribution of the first peripheral compartment}
% \newacronym[sort=V3]{V3}{\ensuremath{\mathrm{V_3}}}{volume of distribution of the second peripheral compartment}
\newacronym[sort=V1]{V1}{\ensuremath{\mathrm{V_c}}}{central volume of distribution}
\newacronym[sort=VC]{VC}{\ensuremath{\mathrm{V_c}}}{central volume of distribution}
\newacronym[sort=V2]{V2}{\ensuremath{\mathrm{V_2}}}{volume of distribution of the first peripheral compartment}
\newacronym[sort=VP]{VP}{\ensuremath{\mathrm{V_p}}}{peripheral volume of distribution}
\newacronym[sort=V3]{V3}{\ensuremath{\mathrm{V_3}}}{volume of distribution of the second peripheral compartment}
\newacronym[plural=VPCs, firstplural=visual predictive checks (VPCs)]{VPC}{VPC}{visual predictive check}

%%%%%%%%% W
\newacronym{WRES}{WRES}{weighted residuals}
\newacronym{WT}{WT}{baseline body weight}

%%%%%%%%% X
\newacronym[sort=X]{chi2}{\ensuremath{\chi^2}}{chi-squared distribution}
\newacronym{SXPORT}{SAS XPORT}{Statistical Analysis System Transport File Format}

%%%%%%%%% Y

%%%%%%%%% Z